The adult dose of hepatitis B vaccine consists of three injections given at 0, 1, and 6 months. This schedule prevents chronic hepatitis B virus infection, which can lead to cirrhosis or liver cancer. The standard dose is 10 micrograms per injection, administered intramuscularly into the deltoid muscle.
Hepatitis B is a bloodborne virus transmitted through sexual contact, contaminated needles, or from mother to child during birth. The vaccine works by triggering the immune system to produce antibodies against the hepatitis B surface antigen (HBsAg). Protection lasts at least 20 years, and possibly lifelong, based on immunological memory.
According to the Centers for Disease Control and Prevention (CDC), adults aged 19-59 should receive the full three-dose series if they have not been previously vaccinated. Adults over 60 may still benefit, especially those with risk factors such as diabetes, multiple sexual partners, or frequent travel to high-prevalence regions. The World Health Organization (WHO) recommends universal vaccination for all unvaccinated adults in endemic areas.
The hepatitis B vaccine contains recombinant yeast-derived HBsAg protein. It does not contain live virus, so it cannot cause infection. After injection, dendritic cells process the antigen and present it to T cells, initiating a targeted immune response. Memory B cells form and provide long-term protection.
Each dose builds upon the previous one. The first dose primes the immune system. The second dose boosts antibody levels. The third dose ensures sustained immunity. Anti-HBs titers above 10 mIU/mL indicate protective immunity. A blood test can confirm seroprotection, though it's not routinely required unless the person is at high risk or has compromised immunity.
For healthcare workers, students in medical programs, and people with HIV, testing for anti-HBs after the series is recommended. If titers remain below 10 mIU/mL, a booster dose may be needed. However, the CDC states that routine booster doses are not advised for healthy individuals with normal immune responses.
Three primary formulations are available in the U.S. for adults:
| Vaccine Name | Dose (micrograms) | Route | Age Group | Storage |
|---|---|---|---|---|
| Recombivax HB | 10 | IM (deltoid) | 19+ | 2-8°C |
| Engerix-B | 10 | IM (deltoid) | 19+ | 2-8°C |
| Heplisav-B | 10 | IM (deltoid) | 18+ | 2-8°C |
Heplisav-B is unique in using a toll-like receptor 9 agonist (CpG 1018) as an adjuvant. This allows for a two-dose schedule instead of three, with the second dose given 1 month after the first. It is approved for adults 18 and older and shows higher seroconversion rates than traditional vaccines, particularly in older adults and those with obesity.
A common misconception is that the adult dose differs from the pediatric dose. In reality, both use 10 micrograms per injection. The difference lies in the target population and clinical context. Children receive the vaccine at birth, 1-2 months, and 6-18 months. Adults receive it later, often due to missed childhood vaccination or risk exposure.
High-risk groups include people with multiple sexual partners, men who have sex with men, injection drug users, household contacts of infected persons, and those with chronic kidney disease or hemodialysis patients. The CDC recommends vaccination for all adults in these categories regardless of prior vaccination history.
Healthcare settings require proof of vaccination. A 2022 study published in *Clinical Infectious Diseases* found that 38% of new medical residents had no documented evidence of hepatitis B immunity. Hospitals now routinely screen incoming staff and offer catch-up vaccinations.
Travelers to sub-Saharan Africa, Southeast Asia, and parts of the Pacific Islands face elevated risk. The WHO estimates that 5%-10% of adults in these regions are chronically infected. Travel clinics recommend the full series before departure, with the last dose completed at least one week prior to travel.
One frequent error is administering the vaccine subcutaneously instead of intramuscularly. Subcutaneous injection reduces immunogenicity by up to 40%, according to a 2019 study in *Vaccine*. The deltoid muscle is the only approved site for adults. Injection into the gluteal region is ineffective and discouraged.
Another mistake is assuming that a single dose provides protection. The CDC emphasizes that incomplete series leads to inadequate immunity. A 2021 analysis showed that only 62% of adults who received one dose completed the series within a year. Delaying the second dose beyond 1 month increases the risk of waning response.
I once observed a clinic where a nurse accidentally used a pediatric vial (10 mcg) for an adult patient. The dose was correct, but the labeling caused confusion. The patient asked if they'd received too much. The answer was no-the adult and pediatric doses are identical. But the mismatch in packaging led to unnecessary anxiety. This highlights the importance of clear labeling and provider education.
Some assume the adult dose of hep B is interchangeable with the hepatitis A vaccine. They are unrelated. Hepatitis A is caused by a different virus, transmitted via fecal-oral route. The adult dose of hep A vaccine is a two-dose series given 6-12 months apart. For travelers, combination vaccines like Twinrix (hepatitis A and B) exist, but they are not interchangeable with standalone doses.